The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.

@article{Pillai2012TheBA,
  title={The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.},
  author={Rathi N. Pillai and Suresh S Ramalingam},
  journal={Current oncology reports},
  year={2012},
  volume={14 2},
  pages={105-10}
}
The anaplastic lymphoma kinase (ALK) acts as a dominant oncogenic driver following chromosomal rearrangements in certain cancers including non-small cell lung cancer (NSCLC). NSCLC with ALK translocation occurs in a specific subset of patients and results in unique clinical features. Crizotinib is a small molecule inhibitor of ALK kinase that has recently… CONTINUE READING